BioArctic AB (publ) (0RV2.IL)
- Simply Wall St.
Swedish Exchange Growth Companies With High Insider Ownership And 51% Earnings Growth
As global markets navigate through varying economic signals, Sweden's stock market remains a point of interest for investors looking for growth opportunities. Amidst this landscape, companies with high insider ownership and significant earnings growth stand out as potentially resilient choices in uncertain times.
- Simply Wall St.
3 Swedish Exchange Growth Companies With High Insider Ownership And Earnings Growth Of At Least 33%
As global markets experience varied trends with Europe showing signs of recovery and Asia displaying mixed signals, Sweden's market remains a focal point for growth-oriented investors. In such an environment, companies with high insider ownership can signal strong confidence in future prospects, making them particularly compelling in the context of Sweden's robust economic framework.
- PR Newswire
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's Disease
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for less frequent monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous (IV) maintenance dosing. A Prescription Drug User Fee Act (PDUFA) action date is set for January 25, 2025. In the US, Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive
